Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide

Figure 15

(a) The IFN-γ levels in plasma samples measured by ELISA in different dose C16 treated groups. ^a𝑃<0.05 versus normal rats, ^b𝑃<0.05 versus vehicle control rats, and ^c𝑃<0.05 versus 0.5 mg/per day C16 treated EAE rats at 2 weeks after immunization. ^f𝑃<0.05 versus vehicle control rats; ^g𝑃<0.05 versus 0.5 mg/per day C16 treated EAE rats at 8 weeks after immunization. (a) The IFN-γ levels in plasma samples measured by ELISA in C16 late treated group. ^a𝑃<0.05 versus normal rats; ^b𝑃<0.05 versus vehicle control rats; ^c𝑃<0.05 versus 0.5 mg/per day C16 treated EAE rats; ^d𝑃<0.05 versus 1 mg/per day C16 treated EAE rats at 8 weeks after immunization. (c) The TGF-β levels in plasma samples measured by ELISA in different dose C16 treated group. ^a𝑃<0.05 versus normal rats. (d) The TGF-β levels in plasma samples measured by ELISA in C16 late treated group.

(a)

(b)

(c)

(d)